Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 5/1/1995


1.		Phase III Study Comparing Current Diagnostic Modalities to the Radioimmunoguided Surgery System Using 125I-Labeled MOAB CC49 for Intra-Abdominal Metastatic or Recurrent Adenocarcinoma of the Colon and Rectum (Summary Last Modified 05/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				NEO-2-14 NCI-V94-0563

Last Modified: 5/1/1995


2.		Phase III Study Comparing Current Diagnostic Modalities to the Radioimmunoguided Surgery System Using 125I-Labeled MOAB CC49 for Primary Adenocarcinoma of the Colon and Rectum (Summary Last Modified 05/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				NEO-2-13 NCI-V94-0567

Last Modified: 12/1/1998 First Published: 7/1/1998


3.		Phase I/II Study of Radioimmunoguided Surgery/Activated Cellular Therapy (RIGS/ACT) Following Complete Surgical Resection of Intraabdominal Disease in Patients with Recurrent Colorectal Cancer (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				NEO-2-61

Last Modified: 3/1/1995


4.		Phase I Study of 90Y-MOAB CC49 for Unresectable or Metastatic Adenocarcinoma of the Gastrointestinal Tract (Summary Last Modified 03/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 to 65				NCI				UNMC-04194 NCI-B92-0019, B92-0019

Last Modified: 1/1/2000


5.		Phase I Study of 90Y-Labeled MOAB CC-49 plus Interferon Alfa with and without EDTA and DTPA in Patients with Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Supportive care, Treatment				Completed				over 18				NCI				UAB-9445 NCI-B95-0004, B95-0004

Last Modified: 10/1/1900


6.		Phase IA/IB Study of Interferon Gamma plus 90Y-Labeled Monoclonal Antibody CC-49 for Metastatic or Unresectable Gastrointestinal Adenocarcinomas (Summary Last Modified 10/00)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				19 to 70				NCI				UNMC-11796 NCI-B95-0006, B95-0006

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute